N. Nagata

发表

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).

J. Sakamoto, S. Hazama, K. Oba, 2016, Clinical colorectal cancer.

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)

Takao Takahashi, Y. Ogata, Y. Miyake, 2016, Oncology.

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy

M. Ando, I. Hyodo, Y. Harihara, 2020, Cancer Chemotherapy and Pharmacology.

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 -mutant or ampli ﬁ ed tumors

H. Baba, T. Shimoyama, T. Denda, 2015 .

Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.

Masato Nakamura, J. Sakamoto, S. Okazaki, 2016, Anticancer research.

Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO)

J. Sakamoto, S. Morita, M. Gosho, 2015, Cancer Chemotherapy and Pharmacology.

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

J. Sakamoto, S. Morita, M. Shimada, 2013, Cancer Chemotherapy and Pharmacology.

Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.

J. Sakamoto, S. Hazama, K. Oba, 2014, Anticancer research.

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)

E. Oki, Masato Nakamura, J. Sakamoto, 2020, The oncologist.

Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

J. Sakamoto, S. Hazama, K. Oba, 2011, Japanese journal of clinical oncology.

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

J. Sakamoto, Takao Takahashi, S. Hazama, 2015, BMC Cancer.

Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

J. Sakamoto, S. Morita, T. Nagasaka, 2019, Medical Oncology.

Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials

H. Nagano, J. Sakamoto, Y. Suehiro, 2019, Oncology letters.

The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C)

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2018, Journal of Cancer.

A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma

Y. Kodera, Kazuhiro Yoshida, T. Yoshikawa, 2009, Cancer Chemotherapy and Pharmacology.

SAPPHIRE: A randomized phase II study of mFOLFOX6 + panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6 + panitumumab in patients with colorectal cancer.

Masato Nakamura, J. Sakamoto, Takao Takahashi, 2018 .

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results.

S. Noura, K. Oba, N. Minagawa, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter, single‐arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild‐type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell‐free DNA

J. Sakamoto, T. Nagasaka, K. Oba, 2022, International journal of cancer.

Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric Carcinoma

J. Sakamoto, H. Usuki, S. Morita, 2007, Journal of chemotherapy.

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis

J. Sakamoto, S. Morita, T. Kono, 2013, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

J. Sakamoto, K. Hanazaki, K. Oba, 2007, Gastric Cancer.

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study†

J. Sakamoto, H. Baba, K. Oba, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)

Masato Nakamura, J. Sakamoto, K. Oba, 2021, Cancer Chemotherapy and Pharmacology.

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.

J. Sakamoto, S. Noura, K. Oba, 2019, European journal of cancer.

UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI‐treated metastatic colorectal cancer in two prospective studies in Japan

M. Oka, Y. Hamamoto, J. Sakamoto, 2013, Cancer science.

Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer

J. Sakamoto, Y. Kameda, H. Kojima, 2013, Cancer Chemotherapy and Pharmacology.

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)

J. Sakamoto, K. Oba, Kenji Kobayashi, 2016, Oncology letters.

[Current Status of Japanese Traditional Medicine 'Kampo' in Chemotherapy].

N. Nagata, 2015, Gan to kagaku ryoho. Cancer & chemotherapy.

A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer

J. Sakamoto, K. Oba, Michiya Kobayashi, 2006, Gastric Cancer.

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study.

M. Ando, I. Hyodo, Y. Harihara, 2018, Annals of Oncology.

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

H. Nagano, J. Sakamoto, Y. Suehiro, 2018, Journal of Cancer.

A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial

M. Kanda, J. Sakamoto, K. Oba, 2018, Cancer Chemotherapy and Pharmacology.

Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer—biweekly versus standard triweekly XELOX (The ORION Study)

K. Oba, K. Ishibashi, Michiya Kobayashi, 2016, International Journal of Clinical Oncology.

Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study.

J. Sakamoto, A. Nakao, K. Oba, 2009, Hepato-gastroenterology.

Phase II multicenter study of second-line FOLFIRI plus cetuximab (FLIER) in patients with KRAS wild-type metastatic colorectal cancer: Final analysis of survival and additional analysis of BRAF, PI3CA mutations.

J. Sakamoto, Y. Miyake, S. Hazama, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

mFOLFOX6 Plus Panitumumab Versus 5‐FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild‐type Colorectal Carcinoma (SAPPHIRE)—Study Design and Rationale

J. Sakamoto, K. Oba, H. Mishima, 2017, Clinical colorectal cancer.

Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study.

J. Sakamoto, M. Fujii, Takeshi Kato, 2011, Anticancer research.

Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

J. Sakamoto, S. Hazama, K. Oba, 2011, Japanese journal of clinical oncology.

A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study.

Kazuhiro Yoshida, J. Sakamoto, K. Muro, 2018, Oncology letters.

Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study

H. Imamura, M. Matsushima, D. Takahari, 2023, Gastric Cancer.